WO2025037218A1

WO2025037218A1 - Crystalline solvate of relugolix and a process for its preparation

Info

Publication number: WO2025037218A1
Application number: PCT/IB2024/057737
Authority: WO
Inventors: Venkata Raghavendra Charyulu Palle; Suresh Kadam; Sukumar Sinha; Sachin GAVHANE; Shailendra Nilkanth BHADANE; Uddhav Popat CHAUDHAR; Ajit Shankar Mindhe; Namrata Govind RANE; Nikhil Uttam SHELKE; Kartik Sudhir PARANDE; Ravi GANDAMALA; Jagdish Patel; Damini Ramesh SONAWANE
Original assignee: Glenmark Life Sciences Ltd
Current assignee: Alivus Life Sciences Ltd
Priority date: 2023-08-11
Filing date: 2024-08-09
Publication date: 2025-02-20
Anticipated expiration: 2026-02-11

Abstract

The present invention relates to a novel crystalline solvate of relugolix, particularly the dimethylacetamide solvate, and a process for its preparation. Also, the present invention relates to a crystalline dimethylacetamide solvate of relugolix for use in the preparation of crystalline relugolix. The present invention further relates to a process for the preparation of crystalline relugolix.

Description

CRYSTALLINE SOLVATE OF RELUGOLIX AND A PROCESS FOR ITS PREPARATION

PRIORITY

[0001] This application claims the benefit of Indian Provisional Application No. 202321053917 filed on August 11, 2023, entitled “Crystalline solvate of relugolix and a process for its preparation”, the contents of which are incorporated herein by reference.

BACKGROUND OF THE INVENTION

Technical Field

[0002] The present invention relates to a novel crystalline solvate of relugolix, particularly the dimethylacetamide solvate, and a process for its preparation. Also, the present invention relates to a crystalline dimethylacetamide solvate of relugolix for use in the preparation of crystalline relugolix. The present invention further relates to a process for the preparation of crystalline relugolix.

Description of the Related Art

[0003] Relugolix, also known as N-[4-[1-[(2,6-difluorophenyl)methyl]-5- [(dimethylamino]-methyl]-3-(6-methoxy-3-pyridazinyl]-2, 4-dioxo- 1,2,3, 4-tetrahydro- thieno[2,3-d]pyrimidin-6-yl]phenyl]-N'-methoxyurea, is represented by the structure of formula I.

[0004] Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist indicated for the treatment of adult patients with advanced prostate cancer.

[0005] A combination of relugolix, a GnRH receptor antagonist, estradiol, an estrogen, and norethindrone acetate, a progestin, is indicated for the management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) in premenopausal women. [0006] Relugolix is disclosed in published PCT Application No. WO 2004/067535A1 (the WO ‘535 publication).

[0007] Certain solvates of relugolix are known in the art, particularly as reported in a few published PCT applications. WO 2014/051164A2 (the WO ‘164 publication) relates to crystalline tetrahydrofuran solvate of relugolix; WO 2021/069700A1 (the WO ‘700 publication) relates to crystalline dimethyl sulfoxide solvate of relugolix (referred to as crystalline Form XIII); WO 2021/069711 Al (the WO ‘711 publication) relates to various polymorphic forms of relugolix (crystalline Forms II, III, V, VI, VII, VIII, IX, X, XI, XII and amorphous form); and WO 2023/066941A1 (the WO ‘941 publication) relates to crystalline ethanol solvate of relugolix (referred to as crystalline Form XIV).

[0008] The object of the present invention is to provide a novel crystalline solvate of relugolix, particularly the dimethylacetamide solvate of relugolix. The crystalline dimethylacetamide solvate of relugolix of the present invention can be used to prepare other known polymorphs of relugolix. A further object of the invention is to provide a process for the preparation of crystalline relugolix.

SUMMARY OF THE INVENTION

[0009] The present invention provides a crystalline dimethylacetamide solvate of relugolix characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 5.6, 9.3, 10.4, 16.5 and 22.5 ±0.2 degrees 2 theta.

[0010] The present invention provides a crystalline dimethylacetamide solvate of relugolix characterized by a DSC thermogram having an endothermic peak at about 170 ±2°C.

[0011] The present invention also provides a process for the preparation of crystalline dimethylacetamide solvate of relugolix, comprising the steps of:

(a) dissolving relugolix in dimethylacetamide, optionally in the presence of an additional solvent, to form a solution;

(b) obtaining crystalline dimethylacetamide solvate of relugolix from the solution of the step (a); and

(c) isolating the crystalline dimethylacetamide solvate of relugolix.

[0012] The present invention provides a crystalline dimethylacetamide solvate of relugolix for use in the preparation of crystalline relugolix, wherein the crystalline relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3, 8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta.

[0013] The present invention further provides a process for the preparation of crystalline relugolix, comprising the steps of:

(1) providing a mixture containing crystalline dimethylacetamide solvate of relugolix dissolved in an organic solvent;

(2) obtaining crystalline relugolix from the mixture of the step (1); and

(3) isolating the crystalline relugolix, wherein the crystalline relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3, 8.9,

9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta.

[0014] The present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of crystalline relugolix and a pharmaceutically acceptable excipient, wherein the crystalline relugolix is obtained from the crystalline dimethylacetamide solvate as described herein.

[0015] The present invention also provides a process for the preparation of crystalline relugolix, comprising the steps of:

(i) providing a solution of relugolix in dimethyl sulfoxide;

(ii) combining the solution of the step (i) with an C₁-C₆ alcohol solvent to form a mixture;

(iii) obtaining crystalline relugolix from the mixture of the step (ii); and

(iv) isolating the crystalline relugolix, wherein the crystalline relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3,

8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta.

BRIEF DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 is a characteristic X-ray Powder Diffraction Pattern (XRPD) of crystalline dimethylacetamide solvate of relugolix as obtained in Example 1.

[0017] Figure 2 is a Differential Scanning Calorimetry (DSC) thermogram of crystalline dimethylacetamide solvate of relugolix as obtained in Example 1.

[0018] Figure 3 is a Thermogravimetric Analysis (TGA) thermogram of crystalline dimethylacetamide solvate of relugolix as obtained in Example 1. [0019] Figure 4 is a characteristic X-ray Powder Diffraction Pattern (XRPD) of crystalline relugolix as obtained in Example 10.

DETAILED DESCRIPTION OF THE INVENTION

[0020] The present invention provides a novel crystalline dimethylacetamide solvate of relugolix, which is characterized by various techniques as described herein including, X- ray powder diffraction (XRPD) and differential scanning calorimetry (DSC).

[0021] In the context of the present invention, the term “room temperature” means a temperature of about 25°C to about 30°C.

[0022] As used herein, the term “about” refers to any value which lies within the range defined by a number up to 10% of the value.

[0023] In the context of the present invention, the term "substantially illustrated" as used in reference to Figure(s) 1, 2 and 3 may be understood to relate to any crystalline dimethylacetamide solvate of relugolix characterized with the graphical data having small variations, as are well known to the person skilled in the art, in comparison with the Figure(s) 1, 2 or 3.

[0024] In one aspect, the present invention provides a crystalline dimethylacetamide solvate of relugolix.

[0025] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 5.6, 9.3, 10.4, 16.5 and 22.5 ±0.2 degrees 2 theta.

[0026] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is further characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 16.4, 18.4, 18.7 ±0.2 degrees 2 theta.

[0027] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 5.6, 9.3, 10.4, 16.5, 18.4, 22.5 ±0.2 degrees 2 theta.

[0028] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by an X-ray powder diffraction (XRPD) pattern as substantially illustrated in Figure 1.

[0029] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 5.6, 9.3, 10.4, 16.5 and 22.5 ±0.2 degrees 2 theta, which is substantially in accordance with Figure 1.

[0030] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by a DSC thermogram having an endothermic peak at about 170 ±2°C.

[0031] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by a DSC thermogram as substantially illustrated in Figure 2.

[0032] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by a DSC thermogram having an endothermic peak at about 170 ±2°C, which is substantially in accordance with Figure 2.

[0033] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 5.6, 9.3, 10.4, 16.5 and 22.5 ±0.2 degrees 2 theta, and a DSC thermogram having an endothermic peak at about 170 ±2°C.

[0034] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 5.6, 9.3, 10.4, 16.5 and 22.5 ±0.2 degrees 2 theta which is substantially in accordance with Figure 1, and a DSC thermogram having an endothermic peak at about 170 ±2°C which is substantially in accordance with Figure 2.

[0035] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by a thermogravimetric analysis (TGA) thermogram, showing a weight loss of about 0 weight % to 20.69 weight % determined over the temperature range of 0°C to 250°C and heating rate of 10°C/min.

[0036] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by a TGA thermogram as substantially illustrated in Figure 3.

[0037] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by a thermogravimetric analysis (TGA) thermogram, showing a weight loss of about 0 weight % to 20.69 weight % determined over the temperature range of 0°C to 250°C and heating rate of 10°C/min, which is substantially in accordance with Figure 3.

[0038] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by gas chromatography analysis, showing presence of about 17.02 % of dimethylacetamide in residual solvent analysis. [0039] In one embodiment, the crystalline dimethylacetamide solvate of relugolix is characterized by an X-ray powder diffraction (XRPD) pattern as depicted in Figure 1, a DSC thermogram as depicted in Figure 2; a thermogravimetric analysis (TGA) as depicted in Figure 3, and any combination of the Figure(s) 1, 2 and 3.

[0040] In another aspect, the present invention provides a process for the preparation of crystalline dimethylacetamide solvate of relugolix, comprising the steps of:

(c) isolating the crystalline dimethylacetamide solvate of relugolix.

[0041] In the context of the present invention relating to the process for the preparation of crystalline dimethylacetamide solvate of relugolix, the term “optionally” means dissolving relugolix in dimethylacetamide, either in the presence of an additional solvent or in the absence of an additional solvent.

[0042] In one embodiment, the additional solvent used in the step (a) is selected from the group consisting of C₁-C₆ alcohol such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutyl alcohol, sec -butyl alcohol, tert-butyl alcohol, n-pentyl alcohol and the like; a C₁-C₆ haloalkane such as dichloromethane, chloroform, dichloroethane and the like; C₂-C₄ sulfoxide such as dimethyl sulfoxide, diethyl sulfoxide and the like; water; and a mixture thereof.

[0043] In one embodiment, the step (a) is carried out at a temperature of about 30°C to about 50°C.

[0044] In one embodiment, the step (a) is carried out at a temperature of about 35°C to about 45°C.

[0045] In one embodiment, the molar ratio of relugolix to dimethylacetamide used in the step (a) is in the range of about 1 to 1 to about 1 to 2.5.

[0046] In one embodiment, the step (b) of obtaining the crystalline dimethylacetamide solvate of relugolix comprises:

(bi) cooling and stirring the solution obtained in the step (a); or

(bii) removing the solvent from the solution obtained in the step (a); or (biii) treating the solution of the step (a) with an anti-solvent to form a mixture and optionally, cooling and stirring the obtained mixture.

[0047] In one embodiment, in the step (bi), the cooling is carried out to a temperature of below about 30°C.

[0048] In the context of the present invention, the term “below about 30°C” as used herein means the temperature ranging from about 30°C to about 15°C, preferably about 30°C to about 20°C, more preferably about 30°C to about 25°C.

[0049] In one embodiment, in the step (bi), the solution of the step (a) is cooled to a temperature ranging from about 30°C to about 20°C.

[0050] In one embodiment, in the step (bi), the solution of the step (a) is cooled to a temperature ranging from about 30°C to about 25°C.

[0051] In one embodiment, in the step (bi), the solution of the step (a) may be stirred for a suitable time. The stirring time may range from about 30 minutes to about 10 hours, or longer.

[0052] In one embodiment, stirring in the step (bi) may be continued for any desired time period to obtain the crystalline dimethylacetamide solvate of relugolix.

[0053] In one embodiment, in the step (bi), the solution of the step (a) is stirred for a period ranging from about 1 hour to about 2 hours.

[0054] In one embodiment, in the step (bi), the solution of the step (a) is stirred for a period ranging from about 1 hour to about 2 hours at a temperature ranging from about 40°C to about 45°C.

[0055] In one embodiment, in the step (bii), the crystalline dimethylacetamide solvate of relugolix is obtained by removing the solvent from the solution obtained in the step (a). Removal of solvent may be accomplished by substantially complete evaporation of the solvent; or concentrating the solution, cooling the solution, if required and filtering the obtained solid. The solution may also be completely evaporated in, for example, a rotavapor, a vacuum paddle dryer or in a conventional reactor under vacuum above about 720mm Hg.

[0056] In one embodiment, in the step (biii), the crystalline dimethylacetamide solvate of relugolix is obtained by adding an anti- solvent to the solution obtained in the step (a) to form a mixture and optionally, cooling and stirring the obtained mixture. [0057] In one embodiment, in the step (biii), the anti- solvent is selected such that the dimethylacetamide solvate of relugolix is precipitated out from the solution.

[0058] In one embodiment, the anti-solvent used in the step (biii) is selected from the group consisting of methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n- butyl alcohol, isobutyl alcohol, sec-butyl alcohol, tert-butyl alcohol, n-pentyl alcohol, water, and a mixture thereof.

[0059] In one embodiment, in the step (c) of the above process, the crystalline dimethylacetamide solvate of relugolix is isolated by any method known in the art. The method, may involve any of techniques, known in the art, including filtration by gravity or by suction, centrifugation, and the like.

[0060] In one embodiment, the isolated crystalline dimethylacetamide solvate of relugolix may be further dried. Drying may be suitably carried out in an equipment conventionally used in the art for the purpose, such as a tray drier, a vacuum oven, an air oven, a fluidized bed drier, a spin flash drier, a flash drier and the like. The drying may be carried out at a temperature ranging from about room temperature to about 100°C with or without vacuum. The drying may be carried out for any desired time until the product having the desired quality is obtained. The drying time may vary from about 1 hour to about 25 hours, or longer.

[0061] In one embodiment, the present invention provides a process for the preparation of crystalline dimethylacetamide solvate of relugolix, comprising the steps of:

(a) dissolving relugolix in dimethylacetamide to form a solution;

(c) isolating the crystalline dimethylacetamide solvate of relugolix.

[0062] In one embodiment, the steps (a), (b) and (c) are carried out as discussed herein above.

[0063] In one embodiment, the present invention provides a process for the preparation of crystalline dimethylacetamide solvate of relugolix, comprising the steps of:

(a) dissolving relugolix in dimethylacetamide to form a solution;

(b) obtaining crystalline dimethylacetamide solvate of relugolix from the solution of the step (a) by cooling and stirring the solution obtained in the step (a); and

(c) isolating the crystalline dimethylacetamide solvate of relugolix. [0064] In one embodiment, the step (a) is carried out at a temperature of about 30°C to about 50°C.

[0065] In one embodiment, the molar ratio of relugolix to dimethylacetamide used in the step (a) is in the range of about 1 to 1 to about 1 to 2.5.

[0066] In one embodiment, in the step (b), the cooling is carried out to a temperature of below about 30°C.

[0067] In one embodiment, in the step (b), the solution of the step (a) is cooled to a temperature ranging from about 30°C to about 20°C.

[0068] In one embodiment, in the step (c) of the above process, the crystalline dimethylacetamide solvate of relugolix is isolated by any method known in the art. The method, may involve any of techniques, known in the art, including filtration by gravity or by suction, centrifugation, and the like.

[0069] In another aspect, the present invention provides a crystalline dimethylacetamide solvate of relugolix for use in the preparation of crystalline relugolix, wherein the crystalline relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3, 8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta.

[0070] In another aspect, the present invention provides a process for the preparation of crystalline relugolix, comprising the steps of:

(2) obtaining crystalline relugolix from the mixture of the step (1); and

(3) isolating the crystalline relugolix, wherein the crystalline relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3, 8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta.

[0071] In one embodiment, in the step (1), the organic solvent is selected from the group consisting of C₁-C₆ alcohol such as methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutyl alcohol, sec -butyl alcohol, tert-butyl alcohol, and n-pentyl alcohol and the like; C2-C4 sulfoxide such as dimethyl sulfoxide, diethyl sulfoxide; and the like; C₁-C₆ haloalkane such as dichloromethane, dichloroethane, chloroform and the like; and a mixture thereof. [0072] In one embodiment, the step (1) is carried out at a temperature of about 30°C to about 60°C.

[0073] In one embodiment, the step (1) is carried out at a temperature of about 35 °C to about 45°C.

[0074] In one embodiment, the step (2) of obtaining crystalline relugolix comprises cooling the mixture of the step (1).

[0075] In one embodiment, in the step (2), the cooling is carried out to a temperature of below about 30°C.

[0076] In one embodiment, in the step (2), the mixture of the step (1) is cooled to a temperature ranging from about 30°C to about 20°C.

[0077] In one embodiment, in the step (2), the mixture of the step (1) is cooled to a temperature ranging from about 30°C to about 25°C.

[0078] In one embodiment, in the step (3), the crystalline relugolix is isolated by any method known in the art. The method, may involve any of techniques, known in the art, including filtration by gravity or by suction, centrifugation, and the like.

[0079] In an embodiment of the present invention, crystalline relugolix prepared from dimethylacetamide solvate of relugolix, is obtained in substantially pure form.

[0080] As used herein, the term “substantially pure,” when used in reference to the crystalline form of relugolix, indicates purity of the crystalline form greater than 90 %, including greater than 90, 91, 92, 93, 94, 95, 96, 97, 98 and 99 % as determined using high performance liquid chromatography (HPLC).

[0081] In another aspect, the present invention also provides a process for the preparation of crystalline relugolix, comprising the steps of:

(i) providing a solution of relugolix in dimethyl sulfoxide;

(ii) combining the solution of the step (i) with an C₁-C₆ alcohol to form a mixture;

(iii) obtaining crystalline relugolix from the mixture of the step (ii); and

(iv) isolating the crystalline relugolix, wherein the crystalline relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3, 8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta.

[0082] In one embodiment, the step (i) is carried out at a temperature of about 25 °C to about 60°C. [0083] In one embodiment, the step (i) is carried out at a temperature of about 25°C to about 45°C.

[0084] In one embodiment, in step (i), the solution may be stirred for a suitable time. Stirring may be continued for any desired time period to achieve a complete dissolution of relugolix.

[0085] In one embodiment, the C₁-C₆ alcohol is selected from methyl alcohol, ethyl alcohol, n-propyl alcohol, isopropyl alcohol, n-butyl alcohol, isobutyl alcohol, sec -butyl alcohol, tert-butyl alcohol, n-pentyl alcohol, or a mixture thereof.

[0086] In the context of the present invention, the term “combining” means adding the solution of the step (i) to an C₁-C₆ alcohol solvent, or adding an C₁-C₆ alcohol solvent to the solution of the step (i).

[0087] In one embodiment, the step (ii) comprises adding the solution of the step (i) to Ci-C₆ alcohol or adding C₁-C₆ alcohol to the solution of the step (i).

[0088] In one embodiment, the step (ii) is carried out at a temperature of about 35 °C to about 70°C.

[0089] In one embodiment, the step (ii) is carried out at a temperature of about 45 °C to about 50°C.

[0090] In one embodiment, the step (iii) of obtaining crystalline relugolix comprises cooling the mixture of the step (ii).

[0091] In one embodiment, in the step (iii), the cooling of the mixture of the step (ii) is carried out to a temperature of below about 30°C.

[0092] In one embodiment, in the step (iii), the mixture of step (ii) is cooled to a temperature of about 30°C to about 20°C.

[0093] In one embodiment, in the step (iii), the mixture of the step (ii) is cooled to a temperature of about 30°C to about 25°C.

[0094] In the step (iv) of the above process, relugolix, the compound I, is isolated from the solution by any method known in the art. The method, may involve any of the techniques, known in the art, including filtration by gravity or by suction, centrifugation, and the like.

[0095] In one embodiment, the crystalline form of relugolix obtained as per the process of the present invention is substantially free of crystalline Form XIII of relugolix and crystalline Form XIV of relugolix. [0096] In one embodiment, the term "substantially free" means the amount referred to is in no detectable quantity.

[0097] In the context of the present invention relating to the process for the preparation of crystalline form of relugolix, the term "no detectable quantity" refers to crystalline Form XIII of relugolix and crystalline Form XIV of relugolix in an amount of less than about 0.5% w/w. Preferably, less than about 0.1%w/w, still more preferably, absent.

[0098] In an embodiment, the crystalline dimethylacetamide solvate of relugolix of the present invention may have a D90 particle size of less than about 250 microns, preferably less than about 150 microns, more preferably less than about 50 microns, still more preferably less than about 20 microns, still more preferably less than about 15 microns, and most preferably less than about 10 microns.

[0099] In an embodiment, the crystalline dimethylacetamide solvate of relugolix of the present invention may have a D50 particle size of less than about 250 microns, preferably less than about 150 microns, more preferably less than about 50 microns, still more preferably less than about 20 microns, still more preferably less than about 15 microns, and most preferably less than about 10 microns.

[0100] In an embodiment, the present invention relates to a pharmaceutical composition comprising crystalline relugolix and at least one pharmaceutically acceptable excipient, wherein the crystalline relugolix is prepared from the dimethylacetamide solvate of relugolix as described herein.

[0101] In an embodiment, the crystalline relugolix contained in the pharmaceutical composition of the present invention may have a D90 particle size of less than about 250 microns, preferably less than about 150 microns, more preferably less than about 50 microns, still more preferably less than about 20 microns, still more preferably less than about 15 microns, and most preferably less than about 10 microns.

[0102] In an embodiment, the crystalline relugolix contained in the pharmaceutical composition of the present invention may have a D50 particle size of less than about 250 microns, preferably less than about 150 microns, more preferably less than about 50 microns, still more preferably less than about 20 microns, still more preferably less than about 15 microns, and most preferably less than about 10 microns.

[0103] The particle size disclosed herein can be obtained by, for example, any milling, grinding, micronizing or other particle size reduction method known in the art to bring the solid state relugolix or solvate thereof into any of the foregoing desired particle size range.

[0104] The examples that follow are provided to enable one skilled in the art to practice the invention, and are merely illustrative of the invention. The examples should not be read as limiting the scope of the invention as defined in the features and advantages.

EXAMPLES

[0105] GENERAL METHODS:

The present invention provides the crystalline dimethylacetamide solvate of relugolix, obtained by the above processes, as characterized and analyzed by the following techniques:

A. X-ray powder diffraction profile was obtained using an X-ray Diffractometer: Empyrean X-Ray Diffractometer

B. DSC: TA DSC.250

Temperature range is 30°C to 300°C and heating rate is 10°C/minute.

C. Thermo Gravimetric Analyzer: TGA Q500 V20. 13 Build 39. Thermogram was recorded at 30-250°C at the rate of 10°C/min.

[0106] EXAMPLE 1: Preparation of dimethylacetamide solvate of relugolix

Relugolix (10g) taken in dimethylacetamide (22mL) was stirred at a temperature ranging from about 35°C to about 45°C for about 50-60 min. The reaction mixture was cooled to a temperature of about 20-30°C and stirred for about 50-60 min. The resulting solid was filtered, washed with dimethylacetamide and dried under reduced pressure for about 4 hours to about 5 hours to yield titled product as off-white solid.

Yield: 8.2g (82%).

Purity: 99.72% by HPLC

TGA analysis of dimethylacetamide solvate of relugolix:

XRPD peaks of dimethylacetamide solvate of relugolix:

[0107] EXAMPLE 2: Preparation of crystalline relugolix

Dimethylacetamide solvate of relugolix (10g) was dissolved in dimethyl sulfoxide (20 mL) at about 40°C to about 45°C. The reaction mass was filtered, washed with mixture of dimethyl sulfoxide (2mL) and ethyl alcohol (lOmL) to obtain clear filtrate. The filtrate was added in ethyl alcohol (150mL) at about 40°C to about 45°C. The reaction mixture was stirred at about room temperature for about 10-12hr. The solid was filtered, washed with ethyl alcohol and dried under reduced pressure for about 4-5 hr to yield titled product as off-white solid (7g, 70%). Purity: 99.64% by HPLC.

[0108] EXAMPLE 3: Preparation of crystalline relugolix

Dimethylacetamide solvate of relugolix (10g) was dissolved in a mixture of methyl alcohol (12mL) and methylene dichloride (48mL) at about 20°C to about 30°C. The reaction mass was filtered to obtain a clear filtrate. The filtrate was distilled under reduced pressure completely, then methyl alcohol (40mL) was added, and the reaction mixture was stirred at about room temperature for about 10-12 hr. The solid was filtered, washed with methyl alcohol and dried under reduced pressure for about 4-5 hr to yield titled product as off-white solid (8g, 80%). Purity: 99.72% by HPLC. [0109] EXAMPLE 4: Preparation of crystalline relugolix

Relugolix (5 g) was dissolved in dimethylformamide (17.5 mL) at a temperature ranging from about 25°C to about 35°C. The reaction mass was filtered, washed with dimethylformamide (2.5mL) to obtain a filtrate. The filtrate was added in ethyl alcohol (95 mL) at about 45°C to about 55°C and stirred for about 2-3 hr. The reaction mixture was stirred at about room temperature for about 10-12 hr. The solid was filtered, washed with ethyl alcohol and dried under reduced pressure for about 4-5 hr to yield titled product as off-white solid (4.1 g, 82%). Purity: 99.79% by HPLC.

[0110] EXAMPLE 5: Preparation of crystalline relugolix

Relugolix (5 g) was dissolved in dimethyl sulfoxide (9 mL) at about 25°C to about 35°C and ethyl alcohol (5 mL) was added to it. The reaction mass was filtered, washed with mixture of dimethyl sulfoxide and ethyl alcohol to obtain a clear filtrate. The filtrate was added in ethyl alcohol (87 mL) at about 40°C to about 50°C and stirred for about 3-4 hr. The reaction mixture was stirred at about room temperature for about 1-2 hr. The solid was filtered, washed with ethyl alcohol and dried under reduced pressure for about 4-5 hr to yield titled product as off-white solid (4.2 g, 84%).

[0111] EXAMPLE 6: Preparation of crystalline relugolix

Relugolix (10g) was dissolved in dimethyl sulfoxide (18 mL) at about 25°C to about 35°C. The reaction mass was filtered, washed with dimethyl sulfoxide to obtain a filtrate. The filtrate was added to ethyl alcohol (290 mL) at about 40°C to about 50°C and stirred for about 3-4 hr. The reaction mixture was stirred at room temperature for about 1-2 hr. The solid was filtered, washed with ethyl alcohol and dried under reduced pressure for about 4-5 hr to yield titled product as off-white solid (8.1 g, 81%).

[0112] EXAMPLE 7: Preparation of 2-((2,6-difluorobenzyl) (ethoxycarbonyl)amino)-4- ((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid Step 1: Preparation of ethyl 5-(4-aminophenyl)-2-((2,6-difluorobenzyl) (ethoxy carbonyl)amino)-4-((dimethylamino)methyl)thiophene-3-carboxylate To the stirred solution of ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4- ((dimethylamino)methyl)-5-(4-nitrophenyl)thiophene-3-carboxylate (10g) and water (50mL) was added acetic acid (lOmL) and hydrogenated over 10% palladium on carbon (50% wet, 0.3g) under 2-3 kg/cm2 hydrogen pressure at about 65-70°C for about 5-6hr. After completion of reaction, reaction mixture was filtered through celite and washed with water. To the clear filtrate were added ethyl acetate and pH was adjusted by adding sodium bicarbonate under stirring. The two layers were separated, and the organic layer containing ethyl 5-(4-aminophenyl)-2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4- ((dimethylamino)methyl)thiophene-3-carboxylate was used as such in the next step. HPLC Purity: 94.99%.

Step 2: Preparation of ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl) amino)-4- ((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylate

To the stirred solution of l,l'-carbonyldiimidazole (4.5g), ethyl acetate (20mL) and triethylamine (1.57g) was added methoxyamine hydrochloride (2.3g) at about 10°C to about 20°C. The reaction mixture was warmed to about 20°C to about 30°C and stirred for about Ihr. The organic layer containing ethyl 5-(4-aminophenyl)-2-((2,6- difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)thiophene-3- carboxylate in ethyl acetate (30mL) of step 1 was added thereto under stirring. The reaction mixture was warmed to about 50°C to about 60°C and stirred for about 2-3hr. After completion of reaction, triethylamine was added (2.21g) at about same temperature under stirring. After cooling the reaction mixture, water was added under stirring. The two layers were separated and the organic layer was concentrated under reduced pressure ethyl 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4- (3 -methoxyureido)phenyl)thiophene-3 -carboxylate as an oil. HPLC Purity: 96.19%.

Step 3: Preparation of 2-((2,6-difluorobenzyl)(ethoxycarbonyl)amino)-4- ((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl)thiophene-3-carboxylic acid

To the stirred solution of compound ethyl 2-((2,6-difluorobenzyl) (ethoxycarbonyl) amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido) phenyl) thiophene-3- carboxylate in methyl alcohol (80mL) was added aqueous sodium hydroxide solution (3.6g sodium hydroxide in 30mL of water). The reaction mixture was warmed to temperature of about 55°C to about 60°C and stirred for about 6-7hr. After completion of reaction, the reaction mixture was cooled to about below 25°C and the pH of the reaction mixture was adjusted to about 6 to about 6.5 by using dilute hydrochloric acid. The reaction mass was concentrated under reduced pressure to obtain an oily residue. To the residue, was added water, dichloromethane and methyl alcohol, and the mixture was stirred for about 4-5hr at about 5 °C to about 15 °C and filtered to obtain wet cake. The obtained wet cake was dissolved in solution of sodium hydroxide in water and to this solution was added dichloromethane and methyl alcohol. The reaction mixture was cooled, and pH of the reaction mixture was adjusted to about 6 to about 6.5 by using dil. hydrochloric acid. The reaction mixture was stirred for about 4-5hr at about 5°C to about 15 °C and filtered to obtain wet cake. The obtained wet cake was again dissolved in solution of sodium hydroxide in water and to this solution was added dichloromethane and methyl alcohol. The reaction mixture was cooled, and pH of the reaction mixture was adjusted to about 6 to about 6.5 by using dil. hydrochloric acid. The reaction mixture was stirred for about 4-5hr at about 5 °C to about 15 °C, filtered, washed with ethyl acetate and dried under reduced pressure to obtain 2-((2,6-difluorobenzyl) (ethoxycarbonyl)amino)- 4-((dimethylamino)methyl)-5-(4-(3-methoxyureido) phenyl) thiophene-3-carboxylic acid as of white to cream yellow solid (1.2g, 69%), HPLC Purity: 99.68%.

[0113] EXAMPLE 8: Preparation of ethyl (2,6-difluorobenzyl)(4-((dimethylamino) methyl)-3-((6-methoxypyridazin-3-yl)carbamoyl)-5-(4-(3-methoxyureido)phenyl) thiophen-2-yl) carbamate

Under a nitrogen atmosphere, to the stirred solution of 2-((2,6-difluorobenzyl) (ethoxycarbonyl)amino)-4-((dimethylamino)methyl)-5-(4-(3-methoxyureido)phenyl) thiophene-3 -carboxylic acid (2.5g) and 3-amino-6-methoxypyridazine (0.66g) in ethyl acetate (7.5mL) and diisopropylethylamine (0.23g) was slowly added 50% propylphosphonic anhydride (T3P) ethyl acetate solution (4.9g) at about 20°C to about 30°C. The reaction mixture was stirred at about same temperature for about 3-4 hr. After completion of the reaction, aqueous sodium bicarbonate solution was added and stirred for about 8hr. The reaction mass was filtered, washed with water followed by ethyl acetate to obtain wet cake. Methyl alcohol was added to the wet cake followed by addition of aqueous sodium bicarbonate solution and the reaction mixture was stirred for about 1-2hr. The reaction mass was filtered and washed with water followed by methyl alcohol. The solid was dried under reduced pressure for about 3-4 hr at about 50°C to about 60°C to yield ethyl (2,6- difluorobenzyl)(4-((dimethylamino)methyl)-3-((6-methoxypyridazin-3-yl)carbamoyl)-5-(4- (3-methoxyureido) phenyl) thiophen-2-yl) carbamate as off-white solid (2.5g, 84%). HPLC Purity: 98.16%.

[0114] EXAMPLE 9: Preparation of Relugolix

To the stirred solution of ethyl (2,6-difluorobenzyl)(4-((dimethylamino)methyl)-3-((6- methoxypyridazin-3-yl)carbarnoyl)-5-(4-(3-methoxyureido)phenyl)thiophen-2-yl) carbamate (2g) in methyl alcohol (8mL) was added 25% sodium methoxide solution (0.3g). The mixture was stirred at about 45 °C to about 50°C for about 2.5hr. After completion of reaction, the reaction mixture was cooled and stirred at temperature of about 20°C to about 30°C for about 5hr. The solid was filtered, washed with methyl alcohol. Water was added to the wet cake and the mixture was stirred for about Ihr. The reaction mass was filtered, washed with water followed by methyl alcohol. The solid was dried under reduced pressure for about 3-4hr at about 50°C to about 60°C to yield (1-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxypyridazin-3-yl)-2,4-dioxo- 1 ,2,3 ,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-3-methoxyurea (1.54g, 83%). HPLC Purity: 99.33%.

[0115] EXAMPLE 10: Preparation of crystalline relugolix

Relugolix (6 g) was dissolved in dimethyl sulfoxide (10.8 mL) at about 25°C to about 45°C. The reaction mass was filtered, washed with dimethyl sulfoxide (1.2 mL) to obtain a filtrate. The filtrate was slowly added in ethyl alcohol (78 mL) at about 45 °C to about 50°C and the resulting mixture was stirred at about 45°C to about 50°C for about 4-5hr. The reaction mixture was gradually cooled to about 35°C to about 25°C for about 2-3hr. The solid was filtered, washed with ethyl alcohol and dried under reduced pressure at about 50°C to about 60°C for about 6-7 hr to obtain product (4.8g, 81%).

HPLC Purity: 99.73%.

XRD: 7.3, 8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta

The crystalline form of relugolix has no detectable quantity of Form XIII of relugolix and Form XIV of relugolix as determined by absence of characteristic peak reflections at about 5.6+0.2 degrees 2 theta and 8.38+0.2 degrees 2 theta respectively. Stability data of crystalline relugolix prepared by the process of the present invention at periodic intervals:

ND- not detected

Claims

1. A crystalline dimethylacetamide solvate of relugolix characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 5.6, 9.3, 10.4, 16.5 and 22.5 ±0.2 degrees 2 theta.

2. A crystalline dimethylacetamide solvate of relugolix characterized by a differential scanning calorimetry (DSC) thermogram having an endothermic peak at about 170 ±2°C.

3. The crystalline dimethylacetamide solvate of claim 1, characterized by an X-ray powder diffraction (XRPD) pattern as substantially illustrated in Figure 1.

4. The crystalline dimethylacetamide solvate of claim 2, characterized by a DSC thermogram as substantially illustrated in Figure 2.

5. The crystalline dimethylacetamide solvate of claim 1 or claim 2, characterized by a thermogravimetric analysis (TGA) thermogram, showing a weight loss of about 0 weight% to 20.69 weight% determined over the temperature range of 0°C to 250°C and heating rate 10°C/min.

6. The crystalline dimethylacetamide solvate of any one of the claims 1, 2 and 5, characterized by a TGA thermogram as substantially illustrated in Figure 3.

7. A process for the preparation of crystalline dimethylacetamide solvate of relugolix as defined in any one of the claims 1 to 6, comprising the steps of:

(c) isolating the crystalline dimethylacetamide solvate of relugolix.

8. The process of claim 7, wherein the step (a) is carried out at a temperature ranging from about 30°C to about 50°C.

9 The process of claim 7, wherein the step (b) of obtaining the crystalline dimethylacetamide solvate of relugolix comprises:

(bi) cooling and stirring the solution obtained in the step (a); or

(bii) removing the solvent from the solution obtained in the step (a); or

(biii) treating the solution of the step (a) with an anti-solvent to form a mixture and optionally, cooling and stirring the obtained mixture.

10. The process of claim 9, wherein in the step (bi), the cooling is carried out to a temperature of below about 30°C.

11. The process of claim 9, wherein in the step (biii), the anti-solvent is selected from the group consisting of C₁-C₆ alcohol; water; and a mixture thereof.

12. A process for the preparation of crystalline relugolix, comprising the steps of:

(2) obtaining crystalline relugolix from the mixture of the step (1); and

13. The process of claim 12, wherein in the step (1), the organic solvent is selected from the group consisting of C₁-C₆ alcohol, C₂-C₄ sulfoxide, C₁-C₆ haloalkane, and a mixture thereof.

14. The process of claim 12 or claim 13, wherein the step (1) is carried out at a temperature ranging from about 30°C to about 60°C.

15. The process of claim 12, wherein the step (2) of obtaining crystalline relugolix comprises cooling the mixture of the step (1).

16. The process of claim 15, wherein the cooling is carried out to a temperature of below about 30°C.

17. A crystalline dimethylacetamide solvate of relugolix for use in the preparation of crystalline relugolix, wherein the crystalline relugolix is characterized by an X-ray powder diffraction (XRPD) spectrum having peak reflections at about 7.3, 8.9, 9.9, 12.0, 16.6, 17.3, 22.2, 22.7, and 27.4 ±0.2 degrees 2 theta.

18. A process for the preparation of crystalline relugolix, comprising the steps of:

(i) providing a solution of relugolix in dimethyl sulfoxide;

(iii) obtaining crystalline relugolix from the mixture of the step (ii); and

19. The process of claim 18, wherein the step (i) is carried out at a temperature of about 25°C to about 60°C.

20. The process of claim 18, wherein the step (ii) is carried out at a temperature of about 35°C to about 70°C.

21. The process of claim 18, wherein the step (iii) of obtaining crystalline relugolix comprises cooling the mixture of the step (ii).

22. The process of claim 21, wherein the cooling is carried out to a temperature of below about 30°C.

23. The process of any one of claims 18 to 22, wherein the crystalline relugolix is substantially free of crystalline Form XIII of relugolix and crystalline Form XIV of relugolix.